Loading clinical trials...
Loading clinical trials...
Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.
The purpose of this study is to determine the negative predictive value of protein S100B that could exclude subarachnoid and intracranial haemorrhage for patient that present severe headache within the last 3 hours.
This study will be proposed to every patient that correspond to eligibility criteria, such as presenting a severe headache (Visual Analog Scale ≥ 6/10) within 3 hours before arriving to the emergency. After signing the informed consent, a blood sample will be taken in order to dosage S100B protein of each patient, and then they will have a brain scan. The trial ends after the brain scan for each patient. Results of brain scans will be compared with results of S100B dosage.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hôpital d'Instruction des Armées Laveran
Marseille, Bouches-du-Rhône, France
Hôpital d'Instruction des Armées Sainte Anne
Toulon, Var, France
Centre Hospitalier Intercommunal de Toulon La Seyne-sur-Mer
Toulon, Var, France
Start Date
October 24, 2018
Primary Completion Date
January 24, 2020
Completion Date
January 24, 2020
Last Updated
October 13, 2022
63
ACTUAL participants
Lead Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
NCT05548530
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07466719